SBIR

The Centers for Disease Control and Prevention is forecasting a research initiative under the SBIR program focused on implementing pharmacist-prescribed access to hormonal contraceptives. This effort aims to expand reproductive health options by enabling licensed pharmacists to prescribe and dispense hormonal birth control without requiring a prior physician visit, thereby improving accessibility, particularly in underserved areas. The project will involve developing, testing, and evaluating protocols, training materials, and system integration frameworks necessary to support safe and effective pharmacist-led contraceptive care within community pharmacy settings. The initiative targets the advancement of public health strategies through innovation in healthcare delivery models, leveraging pharmacy-based services to reduce barriers such as provider shortages, geographic limitations, and appointment delays. The National Institute of Health's SBIR framework indicates that funding will be available for small businesses to conduct research and development activities focused on practical, scalable solutions. A designated program point of contact is listed for inquiries, and the work is expected to align with broader CDC goals to enhance contraceptive access and reduce unintended pregnancies across the United States. The forecast, posted in May 2026, signals an upcoming opportunity for eligible entities to engage in this critical public health project.